Compare GSK plc (GSK) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs LyondellBasell Industries NV — how do they compare? GSK plc trades at $52.64 (market cap $101.34B), while LyondellBasell Industries NV trades at $58.74 (market cap $18.72B). The key difference: GSK plc is far larger — about 5.4× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (7.1%). Which is the better fit depends on your goals.
| GSK | LYB | |
|---|---|---|
Market Cap | $101.34B | $18.72B |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $82.38 |
52-Week Low | $36.20 | $42.28 |
Enterprise Value | $121.95B | $30.34B |
Dividend Yield | 3.49% | 7.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
LYB trades at $58.79, up 0.4% on the day, with a bullish technical signal and positive analyst consensus. The stock shows mixed fundamentals with declining revenue and negative net income margins, though recent earnings beats and strategic partnerships in sustainable packaging provide optimism. Cash flow remains positive, and the company maintains a dividend, supporting income-focused investors amid cyclical challenges.
Outlook is cautiously optimistic with a consensus price target of $73.11 implying 24% upside, but risks include persistent margin pressure, high debt, and industry headwinds. Investment appeal hinges on execution of cost-cutting and recycling initiatives, with volatility expected near Q2 earnings on July 31, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
